Trial Profile
Inhibition of DNA Methylation by 1-hr Infusion of 5-aza-2'-Deoxycytidine (Decitabine) x 10 Days (M-F) With Escalating Doses of Sub-Q Pegylated (PEG) Interferon-alfa 2B (PEG-Intron): A Phase I Study With Molecular Correlates
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 19 Jul 2011 Actual initiation date (Apr 2009) added as reported by ClinicalTrials.gov
- 19 Jul 2011 Planned end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 17 Nov 2008 Integrated ClinicalTrials.gov record.